OBJECTIVES: To evaluate the response to treatment given on a large scale for hepatitis B and C through a nationwide programme. METHODS: Records of patients who received treatment of hepatitis B and C during past 2 years through the Prime Minister's programme for the Prevention and Control of Hepatitis Viral Infection was retrieved randomly from 12 sites after taking consent from the management and the site managers. Data confidentiality was ensured. All data was photocopied and brought to the Pakistan Medical Research Centre at the Jinnah Postgraduate Medical Centre, Karachi, where it was entered and analysed. The inclusion/exclusion criteria and the followup tests that were to be done before, during and after treatment were taken from the National programme manager so that actual data could be matched with the guidelines. Data was analysed through a specially developed programme. RESULTS: A total of 7752 patients received treatment at the 12 sites for hepatitis C. Adherence to inclusion/exclusion criteria or protocol was followed in 7572 (97.6%) patients. Out of 7572 patients, 3440 (45.4%) completed 6 months of interferon therapy, but the polymerase chain reaction test at the end of 6 months was available in 1686 (49%) cases. It was not detected at 6 months in 1133/1686 (67%) cases, while in 553 (33%) cases there was no response. Data for hepatitis B was collected from 8 sites. A total of 454 cases received treatment and 85 (18.72%) fulfilled the inclusion criteria. Treatment was completed by 9 (10.58%) cases, with 3 (3.52%) cases showing Hepatitis B 'e' antigen clearance and anti-HBe (antibody to hepatitis B 'e' antigen) production. CONCLUSION: Poor followup and inadequate documentation of serological/biochemical tests were the major drawbacks in both hepatitis B and C patients, resulting in wastage of huge human and financial resources without proper planning and accountability.
OBJECTIVES: To evaluate the response to treatment given on a large scale for hepatitis B and C through a nationwide programme. METHODS: Records of patients who received treatment of hepatitis B and C during past 2 years through the Prime Minister's programme for the Prevention and Control of Hepatitis Viral Infection was retrieved randomly from 12 sites after taking consent from the management and the site managers. Data confidentiality was ensured. All data was photocopied and brought to the Pakistan Medical Research Centre at the Jinnah Postgraduate Medical Centre, Karachi, where it was entered and analysed. The inclusion/exclusion criteria and the followup tests that were to be done before, during and after treatment were taken from the National programme manager so that actual data could be matched with the guidelines. Data was analysed through a specially developed programme. RESULTS: A total of 7752 patients received treatment at the 12 sites for hepatitis C. Adherence to inclusion/exclusion criteria or protocol was followed in 7572 (97.6%) patients. Out of 7572 patients, 3440 (45.4%) completed 6 months of interferon therapy, but the polymerase chain reaction test at the end of 6 months was available in 1686 (49%) cases. It was not detected at 6 months in 1133/1686 (67%) cases, while in 553 (33%) cases there was no response. Data for hepatitis B was collected from 8 sites. A total of 454 cases received treatment and 85 (18.72%) fulfilled the inclusion criteria. Treatment was completed by 9 (10.58%) cases, with 3 (3.52%) cases showing Hepatitis B 'e' antigen clearance and anti-HBe (antibody to hepatitis B 'e' antigen) production. CONCLUSION: Poor followup and inadequate documentation of serological/biochemical tests were the major drawbacks in both hepatitis B and C patients, resulting in wastage of huge human and financial resources without proper planning and accountability.
Authors: Yuely A Capileno; Rafael Van den Bergh; Dmytro Donchunk; Sven Gudmund Hinderaker; Saeed Hamid; Rosa Auat; Gul Ghuttai Khalid; Razia Fatima; Aashifa Yaqoob; Catherine Van Overloop Journal: PLoS One Date: 2017-04-27 Impact factor: 3.240
Authors: Aaron G Lim; Huma Qureshi; Hassan Mahmood; Saeed Hamid; Charlotte F Davies; Adam Trickey; Nancy Glass; Quaid Saeed; Hannah Fraser; Josephine G Walker; Christinah Mukandavire; Matthew Hickman; Natasha K Martin; Margaret T May; Francisco Averhoff; Peter Vickerman Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Gul Ghuttai Khalid; Khine Wut Yee Kyaw; Christine Bousquet; Rosa Auat; Dmytro Donchuk; Adam Trickey; Saeed Hamid; Huma Qureshi; Valentina Mazzeo; Khawar Aslam; Salima Khowaja; Rafael Van den Bergh Journal: Int Health Date: 2020-01-01 Impact factor: 2.473
Authors: Nyashadzaishe Mafirakureva; Aaron G Lim; Gul Ghuttai Khalid; Khawar Aslam; Linda Campbell; Hassaan Zahid; Rafael Van den Bergh; Gregoire Falq; Camille Fortas; Yves Wailly; Rosa Auat; Dmytro Donchuk; Anne Loarec; Joanna Coast; Peter Vickerman; Josephine G Walker Journal: J Viral Hepat Date: 2020-11-04 Impact factor: 3.728